Evolus, Inc. (EOLS)

$12.09

-0.6

(-4.73%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Evolus, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 49.32M → 60.99M (in $), with an average increase of 19.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -18.14M → -11.83M (in $), with an average increase of 25.1% per quarter

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 41.7% return, outperforming this stock by 34.4%

Performance

  • $11.97
    $12.61
    $12.09
    downward going graph

    0.99%

    Downside

    Day's Volatility :5.04%

    Upside

    4.09%

    downward going graph
  • $7.07
    $15.43
    $12.09
    downward going graph

    41.52%

    Downside

    52 Weeks Volatility :54.18%

    Upside

    21.65%

    downward going graph

Returns

PeriodEvolus, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
15.92%
-1.1%
0.0%
6 Months
45.66%
6.7%
0.0%
1 Year
49.81%
3.2%
-0.7%
3 Years
7.28%
15.2%
-21.6%

Highlights

Market Capitalization
785.3M
Book Value
- $0.36
Earnings Per Share (EPS)
-1.08
Wall Street Target Price
22.29
Profit Margin
-30.52%
Operating Margin TTM
-8.33%
Return On Assets TTM
-12.3%
Return On Equity TTM
-1279.29%
Revenue TTM
202.1M
Revenue Per Share TTM
3.55
Quarterly Revenue Growth YOY
39.800000000000004%
Gross Profit TTM
92.7M
EBITDA
-31.0M
Diluted Eps TTM
-1.08
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.35
EPS Estimate Next Year
0.16
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
-0.08

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Evolus, Inc.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 84.37%

Current $12.09
Target $22.29

Technicals Summary

Sell

Neutral

Buy

Evolus, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Evolus, Inc.
Evolus, Inc.
-13.02%
45.66%
49.81%
7.28%
-51.33%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-3.19%
18.54%
29.33%
41.75%
58.78%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-3.61%
-2.91%
-7.72%
8.1%
8.1%
Zoetis Inc.
Zoetis Inc.
-13.09%
-14.39%
-14.11%
-9.35%
48.11%
Viatris Inc.
Viatris Inc.
-5.11%
19.64%
14.33%
-14.68%
-30.66%
Catalent, Inc.
Catalent, Inc.
0.14%
21.02%
23.93%
-49.27%
26.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Evolus, Inc.
Evolus, Inc.
NA
NA
NA
-0.35
-12.79
-0.12
NA
-0.36
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
55.91
55.91
0.45
4.77
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.17
28.17
1.71
0.46
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
32.19
32.19
2.81
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
232.9
232.9
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.08
0.45
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Evolus, Inc.
Evolus, Inc.
Buy
$785.3M
-51.33%
NA
-30.52%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.7B
58.78%
55.91
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.3B
8.1%
28.17
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$74.7B
48.11%
32.19
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.8B
-30.66%
232.9
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.3B
26.77%
211.02
-31.77%

Institutional Holdings

  • Nantahala Capital Management, LLC

    9.47%
  • Stonepine Capital Management Llc

    8.67%
  • Perceptive Advisors LLC

    6.44%
  • BlackRock Inc

    5.43%
  • TANG CAPITAL MANAGEMENT LLC

    5.04%
  • Vanguard Group Inc

    4.79%

Corporate Announcements

  • Evolus, Inc. Earnings

    Evolus, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.

Organization
Evolus, Inc.
Employees
273
CEO
Mr. David Moatazedi
Industry
Health Technology

FAQs